Bioprospecting

Many important medications have been discovered by bioprospecting including the diabetes drug metformin (developed from a natural product found in Galega officinalis).^[1]

Intellectual property
Authors' rights Copyleft Copyright Database right Farmers' rights Geographical indication Indigenous intellectual property Industrial design right Integrated circuit layout design protection Intellectual property infringement Literary property Moral rights Patent Peasants' rights Plant breeders' rights Plant genetic resources Proprietary software Related rights Supplementary protection certificate Trade dress Trade secret Trademark Utility model Patent infringement
Related topics
Abandonware Artificial intelligence and copyright Brand protection Copyright abolition Copyright troll Criticism of copyright Bioprospecting Biopiracy Idea–expression distinction Limitations and exceptions to copyright Fair dealing Fair use Paraphrasing Right to quote Orphan work Patent troll Pirate Party Public domain Outline of intellectual property Outline of patents Higher categories: Property and Property law
v t e

Bioprospecting (also known as biodiversity prospecting) is the exploration of natural sources for small molecules, macromolecules and biochemical and genetic information that could be developed into commercially valuable products for the agricultural,^[2][3] aquaculture,^[4][5] bioremediation,^[4][6] cosmetics,^[7][8] nanotechnology,^[4][9] or pharmaceutical^[2][10] industries. In the pharmaceutical industry, for example, almost one third of all small-molecule drugs approved by the U.S. Food and Drug Administration (FDA) between 1981 and 2014 were either natural products or compounds derived from natural products.^[11]

Terrestrial plants, fungi and actinobacteria have been the focus of many past bioprospecting programs,^[12] but interest is growing in less explored ecosystems (e.g. seas and oceans, caves and polar regions)^{[7][13][14][15]} and organisms (e.g. extremophiles, tropical corals and necrophages)^[16][17][18] as a means of identifying new molecules with novel biological activities.^[10] Species may be randomly screened for bioactivity or rationally selected and screened based on ecological, ethnobiological, ethnomedical, historical or genomic information.^[10][19][20]

When a region's biological resources or indigenous knowledge are unethically appropriated or commercially exploited without providing fair compensation, this is known as biopiracy.^[12][21] Various international treaties have been negotiated to provide countries legal recourse in the event of biopiracy and to offer commercial actors legal certainty for investment. These include the UN Convention on Biological Diversity and the Nagoya Protocol.^[2][10] The WIPO is currently negotiating more treaties to bridge gaps in this field.^[22][23]

Other risks associated with bioprospecting are the overharvesting of individual species and environmental damage, but legislation has been developed to combat these also. Examples include national laws such as the US Marine Mammal Protection Act and US Endangered Species Act, and international treaties such as the UN Convention on Biological Diversity, the UN Convention on the Law of the Sea, the Biodiversity Beyond National Jurisdictions Treaty, and the Antarctic Treaty.^[10][24]